title: [Clinical evaluation of ofloxacin in the treatment of chronic complicated urinary tract infection].
abstract: Ofloxacin was administered orally at a daily dosage of 300 mg and 600 mg in three divided doses for 14 days to 24 and 60 patients with chronic complicated urinary infections, respectively, in order to evaluate the therapeutic efficacy. The clinical efficacy was evaluated according to the criterion proposed by the UTI Committee in Japan and its efficacy was evaluated in 84 cases. In the group of 24 patients receiving a daily dosage of 300 mg, the clinical effectiveness after a 5-day treatment was excellent in 13 cases and moderate in 7 cases. The overall clinical efficacy was 83.8%. In the group of 60 patients receiving a daily dosage of 600 mg, the rate of overall clinical efficacy after a 5-day treatment was 83.3%, being excellent in 23 cases and moderate in 27 cases. The eradication rate was 85.3% and 92.5% by 300 mg and 600 mg dosages of ofloxacin, respectively. As adverse reactions, anorexia and nausea occurred in 2 cases. Laboratory anomalies consisted of 1 case of slight and transient elevation of transaminase, and 1 case of elevated serum creatinine.
authors.affiliation: Department of Urology, School of Medicine, Kanazawa University.
authors.forename: T
authors.initials: T
authors.lastname: Uchibayashi
authors.forename: A
authors.initials: A
authors.lastname: Nishino
authors.forename: I
authors.initials: I
authors.lastname: Motoi
authors.forename: H
authors.initials: H
authors.lastname: Hisazumi
authors.forename: M
authors.initials: M
authors.lastname: Sawaki
authors.forename: M
authors.initials: M
authors.lastname: Orito
authors.forename: H
authors.initials: H
authors.lastname: Koizumi
authors.forename: R
authors.initials: R
authors.lastname: Shyoda
authors.forename: K
authors.initials: K
authors.lastname: Nagano
authors.forename: K
authors.initials: K
authors.lastname: Kobashi
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D015242:Ofloxacin